Stratified patient-centered care in type 2 diabetes: A cluster-randomized, controlled clinical trial of effectiveness and cost-effectiveness

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 3054-3061

  Slingerland, Annabelle S ^a,b   Herman, William H ^b   Redekop, William K ^b   Dijkstra, Rob F ^c   Jukema, J Wouter ^a   Niessen, Louis W ^b,d,e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d DUTCH COLLEGE OF GENERAL PRACTITIONERS   (Netherlands)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CARE; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; PATIENT-CENTERED CARE; PROSPECTIVE STUDIES;

EID: 84891869730     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1865     Document Type: Article

References (41)

1. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010;33: 1872-1894
2. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-2551
3. Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ 2003;81:19-27
4. Tarride JE, Hopkins R, Blackhouse G, et al. A review of methods used in longterm cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics 2010;28:255-277
5. World Health Organization. Prevention of Diabetes Mellitus. Report of a WHO Study Group. Geneva, World Health Org., 1994 (Tech. Rep. Ser., no. 844)
6. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365: 1333-1346
7. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787
8. International Diabetes Federation. IDF Diabetes Atlas, Fifth Edition [Internet]. Available from http://www.idf.org/ diabetesatlas/5e/the-global- burden. Accessed 5 June 2013
9. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Wagner EH. Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics 1999;16: 285-295
10. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and costeffectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-744
11. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998;21:1167-1172
12. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854-865
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853
14. van der Heijden AA, Ortegon MM, Niessen LW, Nijpels G, Dekker JM. Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. Diabetes Care 2009;32:2094-2098
15. Cleveringa FG, Welsing PM, van den Donk M, et al. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk. Diabetes Care 2010; 33:258-263
16. Schouten LM, Niessen LW, van de Pas JW, Grol RP, Hulscher ME. Cost-effectiveness of a quality improvement collaborative focusing on patients with diabetes. Med Care 2010;48:884-891
17. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetesmellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140:689-699
18. Mensing C, Boucher J, Cypress M, et al. National standards for diabetes selfmanagement education. Diabetes Care 2006;29(Suppl. 1):S78-S85
19. Gillett M, Dallosso HM, Dixon S, et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost-effectiveness analysis. BMJ 2010;341:c4093
20. Cobden DS, Niessen LW, Barr CE, Rutten FF, Redekop WK. Relationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in type 2 diabetes. Value Health 2010;13: 138-147
21. van 't Riet E, Rijkelijkhuizen JM, Alssema M, et al. HbA1c is an independent predictor of non-fatal cardiovascular disease in a Caucasian population without diabetes: a 10-year follow-up of the Hoorn Study. Eur J Prev Cardiol 2012;19:23-31
22. Ginde AA, Cagliero E, Nathan DM, Camargo CA Jr. Value of risk stratification to increase the predictive validity of HbA1c in screening for undiagnosed diabetes in the US population. J Gen Intern Med 2008; 23:1346-1353
23. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111
24. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995;345:1616-1619
25. Coyle D. Determining the optimal combinations of mutually exclusive interventions: a response to Hutubessy and colleagues. Health Econ 2003;12:159-162; discussion 163-164
26. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored costeffectiveness data. Health Econ 2004;13: 461-475
27. Cao MM, Tong NW. Stratifying and tailoring HbA1c control targets for adults with type 2 diabetes: interpretation of the consensus proposed by the Chinese Society of Endocrinology. J Diabetes 2011;3: 201-207
28. Lauritzen T, Sandbaek A, Skriver MV, Borch-Johnsen K. HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark. Diabetologia 2011; 54:1318-1326
29. Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 2002;20: 443-454
30. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE,Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002; 25:458-463
31. Eastman RC, Javitt JC, HermanWH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997;20:725-734
32. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ 2007;16:307-317
33. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005;331: 446-448
34. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMI 2000;320:1373-1378
35. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641
36. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143: 251-264
37. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-2551
38. Huang ES, Shook M, Jin L, Chin MH, Meltzer DO. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with newonset diabetes. Diabetes Care 2006;29: 259-264
39. Clark LT. Issues in minority health: atherosclerosis and coronary heart disease in African Americans. Med Clin North Am 2005;89:977-1001,994
40. Hauber A, Gale EA. The market in diabetes. Diabetologia 2006;49:247-252
41. Duke SA, Colagiuri S, Colagiuri R. Individual patient education for people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2009;21:CD005268